当前位置： SCI文献检索 > LEUKEMIA期刊下所有文献 > VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

Abstract：

:We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epigallocatechin (EGCG) decreases VEGF receptor phosphorylation and induces apoptosis in CLL B cells. The mechanism(s) by which VEGF receptor activation increases Mcl-1 and XIAP and promotes survival remains unknown. To further define the signaling pathway mediating VEGF induction of antiapoptotic proteins in CLL B-cells, we investigated downstream effects of VEGF-VEGF receptor binding on the STAT signaling pathway. We find that CLL B cells abundantly express cytoplasmic serine phosphorylated (p)-STAT-1 and p-STAT-3, VEGF-R1/2 are physically associated with p-STAT-1 and p-STAT-3, and p-STAT-3 (but not p-STAT-1) is found in the CLL nucleus. VEGF receptor ligation selectively induces activation and perinuclear translocation of STAT 3 through receptor-mediated endocytosis. The inhibition of VEGF receptor activation with either tyrosine kinase inhibitors or VEGF neutralizing antibodies inhibit VEGF receptor phosphorylation, decrease p-STAT-3 (serine 727), Mcl-1, and induces cell death in CLL B cells. Thus, a VEGF-VEGF receptor pathway in CLL B cells can be linked to activation of STAT proteins that are able to enhance their apoptotic resistance.

journal_name

Leukemia

journal_title

Leukemia

authors

Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

doi

10.1038/sj.leu.2403667

subject

Has Abstract

pub_date

2005-04-01 00:00:00

pages

513-23

issue

4

eissn

0887-6924

issn

1476-5551

pii

2403667

journal_volume

19

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.

    abstract：:Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype A...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0550-5

    authors： Cazzola A,Schlegel C,Jansen I,Bochtler T,Jauch A,Krämer A

    更新日期：2019-11-01 00:00:00

  • Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

    abstract：:This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.173

    authors： Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

    更新日期：2017-12-01 00:00:00

  • Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.

    abstract：:Immunotherapy with T cell modified with gamma-retroviral or lentiviral (LV) vectors to express a chimeric antigen receptor (CAR) has shown remarkable efficacy in clinical trials. However, the potential for insertional mutagenesis and genotoxicity of viral vectors is a safety concern, and their cost and regulatory dema...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.180

    authors： Monjezi R,Miskey C,Gogishvili T,Schleef M,Schmeer M,Einsele H,Ivics Z,Hudecek M

    更新日期：2017-01-01 00:00:00

  • Treatment results of three consecutive Brazilian cooperative childhood ALL protocols: GBTLI-80, GBTLI-82 and -85. ALL Brazilian Group.

    abstract：:The Brazilian Cooperative Group for Treatment of Childhood Acute Lymphocytic Leukemia (GBTLI) has started clinical activities trials in 1980. Three consecutive multicenter studies in children with unprevious treated ALL have been completed including 994 patients. The first GBTLI-80 accrued 203 children from 1980 to 19...

    journal_title：Leukemia

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：

    authors： Brandalise S,Odone V,Pereira W,Andrea M,Zanichelli M,Aranega V

    更新日期：1993-08-01 00:00:00

  • Gene deletion explains both in vivo and in vitro generated chromosome 2 aberrations associated with murine myeloid leukemia.

    abstract：:Ninety-five percent of radiation-induced murine myeloid leukemias contain chromosome 2 aberrations. A dominant molecular defect has not yet been identified: both deletions and breakpoint-specific events have been postulated. We have generated a model in which chromosome 2 lesions have been generated in vitro in a clon...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Alexander BJ,Rasko JE,Morahan G,Cook WD

    更新日期：1995-12-01 00:00:00

  • Heterogeneity of VH-JH gene rearrangement patterns: an insight into the biology of B cell precursor ALL.

    abstract：:Oligoclonal B cell proliferation, as defined by the presence of more than one leukemic clone, has been detected in approximately 20% to 30% of patients with acute lymphoblastic leukemia (ALL) using PCR or Southern blotting. An accurate assessment of these populations is required to avoid false negative measurements of...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402234

    authors： Moreira I,Papaioannou M,Mortuza FY,Gameiro P,Palmisano GL,Harrison CJ,Prentice HG,Mehta AB,Hoffbrand AV,Foroni L

    更新日期：2001-10-01 00:00:00

  • Bone marrow stem cell mobilization in stroke: a 'bonehead' may be good after all!

    abstract：:Mobilizing bone cells to the head, astutely referred to as 'bonehead' therapeutic approach, represents a major discipline of regenerative medicine. The last decade has witnessed mounting evidence supporting the capacity of bone marrow (BM)-derived cells to mobilize from BM to peripheral blood (PB), eventually finding ...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/leu.2011.167

    authors： Borlongan CV

    更新日期：2011-11-01 00:00:00

  • A classification based on T cell selection-related phenotypes identifies a subgroup of childhood T-ALL with favorable outcome in the COALL studies.

    abstract：:During T cell selection in the thymic cortex more than 90% of the thymocytes are eliminated by apoptosis. Based on this biology, we propose to define blasts of T cell acute lymphoblastic leukemia (ALL) with the phenotype of cortical thymocytes (CD1+ and/or CD4+ 8+) as selection-related (SR) and all other T-ALL immunop...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401382

    authors： Niehues T,Kapaun P,Harms DO,Burdach S,Kramm C,Körholz D,Janka-Schaub G,Göbel U

    更新日期：1999-04-01 00:00:00

  • Cellular and molecular studies on the early stages of human hematopoietic differentiation in culture of pure progenitors.

    abstract：:Methodology has been developed that enables virtually complete purification and recovery of early hematopoietic progenitors from human adult blood, a minority of which is multipotent and endowed with self-renewal capacities, i.e., exhibits stem cell properties. This report briefly reviews: (i) the key steps involved i...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Pelosi E,Testa U,Gabbianelli M,Valtieri M,Montesoro E,Samoggia P,Mastroberardino G,Isacchi G,Peschle C

    更新日期：1992-11-01 00:00:00

  • Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

    abstract：:Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagno...

    journal_title：Leukemia

    pub_type： 杂志文章,多中心研究

    doi：10.1038/s41375-019-0472-2

    authors： Pollyea DA,Tallman MS,de Botton S,Kantarjian HM,Collins R,Stein AS,Frattini MG,Xu Q,Tosolini A,See WL,MacBeth KJ,Agresta SV,Attar EC,DiNardo CD,Stein EM

    更新日期：2019-11-01 00:00:00

  • Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias.

    abstract：:There is increasing evidence that HOX homeobox genes play a role in leukemogenesis. Recent studies have demonstrated that enforced co-expression of HOXA9 and MEIS1 in murine marrow leads to rapid development of myeloid leukemia, and that these proteins exhibit cooperative DNA binding. However, it is unclear whether co...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401578

    authors： Lawrence HJ,Rozenfeld S,Cruz C,Matsukuma K,Kwong A,Kömüves L,Buchberg AM,Largman C

    更新日期：1999-12-01 00:00:00

  • An atlas of bloodstream-accessible bone marrow proteins for site-directed therapy of acute myeloid leukemia.

    abstract：:The concept of arming antibodies with bioactive payloads for a site-specific therapy of cancer has gained considerable interest in recent years. However, a successful antibody-based targeting approach critically relies on the availability of a tumor-associated target that is not only preferentially expressed in the tu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2017.208

    authors： Angenendt L,Reuter S,Kentrup D,Benk AS,Neumann F,Hüve J,Martens AC,Schwöppe C,Kessler T,Schmidt LH,Sauer T,Brand C,Mikesch JH,Lenz G,Mesters RM,Müller-Tidow C,Hartmann W,Wardelmann E,Neri D,Berdel WE,Roesli C,Sc

    更新日期：2018-02-01 00:00:00

  • Cancer procoagulant in the human promyelocytic cell line NB4 and its modulation by all-trans-retinoic acid.

    abstract：:Acute promyelocytic leukemia (APL) cells express different types of procoagulant activity (PCA), including tissue factor (TF), and cancer procoagulant (CP). The aim of this study was to investigate whether the NB4 cell line, the first ever isolated human APL line, with the typical t(15;17) chromosomal balance transloc...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Falanga A,Consonni R,Marchetti M,Mielicki WP,Rambaldi A,Lanotte M,Gordon SG,Barbui T

    更新日期：1994-01-01 00:00:00

  • Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.

    abstract：:JAK2V617F is the most common mutation in patients with BCR-ABL negative myeloproliferative neoplasms (MPNs). The eradication of JAK2V617F hematopoietic stem cells (HSCs) is critical for achieving molecular remissions and cure. We investigate the distinct effects of two therapies, ruxolitinib (JAK1/2 inhibitor) and int...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-019-0638-y

    authors： Austin RJ,Straube J,Bruedigam C,Pali G,Jacquelin S,Vu T,Green J,Gräsel J,Lansink L,Cooper L,Lee SJ,Chen NT,Lee CW,Haque A,Heidel FH,D'Andrea R,Hill GR,Mullally A,Milsom MD,Bywater M,Lane SW

    更新日期：2020-04-01 00:00:00

  • SIV/HIV-1 chimeric viruses having HIV-1 env gene: a new animal model and a candidate for attenuated live vaccine.

    abstract：:In order to generate an HIV-1, which is infectious to and induces AIDS-like disease in monkeys, an SIVmac/HIV-1 chimeric virus, designated NM-3rN, which was replication-competent in monkeys, was constructed by recombination between HIV-1 and SIV mac genomes. The NM-3rN enabled to evaluate the efficacy of HIV-1 Env-dir...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Hayami M,Igarashi T

    更新日期：1997-04-01 00:00:00

  • Donor leukemia following allogeneic bone marrow transplantation.

    abstract：:Although allogeneic bone marrow transplantation has been shown to be a highly effective treatment for acute and chronic leukemia, leukemic relapse remains a significant problem. Leukemic relapse occurs in recipient cells in the majority of cases, but the paucity of donor cell leukemias may reflect the sensitivity of t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Mc Cann SR,Lawler M,Gardiner N,O'Riordan J,Humphries P,De Arce M

    更新日期：1994-04-01 00:00:00

  • Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

    abstract：:Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment. Bone marrow (BM) stroma has been implicated in the long-term su...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2011.360

    authors： Weisberg E,Azab AK,Manley PW,Kung AL,Christie AL,Bronson R,Ghobrial IM,Griffin JD

    更新日期：2012-05-01 00:00:00

  • Establishment of multipotential and antigen presenting cell lines derived from myeloid leukemias in GM-CSF transgenic mice.

    abstract：:In this study neonatal mice expressing a GM-CSF transgene (GMT mice), and their normal littermate controls, were infected with Moloney murine leukemia virus (MoMLV) to examine in vivo tumorigenesis. By 200 days, all of the GMT mice had died whereas median survival had not been reached in the littermates (P < 0.0003). ...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2400614

    authors： Rasko JE,Metcalf D,Alexander B,Strasser A,Begley CG

    更新日期：1997-05-01 00:00:00

  • Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.

    abstract：:Treatment resistance in T-cell acute lymphoblastic leukemia (T-ALL) is associated with phosphatase and tensin homolog (PTEN) deletions and resultant phosphatidylinositol 3'-kinase (PI3K)-AKT pathway activation, as well as MYC overexpression, and these pathways repress mitochondrial apoptosis in established T-lymphobla...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.78

    authors： Reynolds C,Roderick JE,LaBelle JL,Bird G,Mathieu R,Bodaar K,Colon D,Pyati U,Stevenson KE,Qi J,Harris M,Silverman LB,Sallan SE,Bradner JE,Neuberg DS,Look AT,Walensky LD,Kelliher MA,Gutierrez A

    更新日期：2014-09-01 00:00:00

  • New insight on the role of extrachromosomal retroviral DNA.

    abstract：:During infection with different retroviruses, high levels of unintegrated extrachromosomal DNA accumulate in infected cells. While extrachromosomal linear DNA is the immediate precursor of the integrated provirus, the function, if any, of extrachromosomal circular DNA has been unclear. Several groups have attempted to...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2400776

    authors： Cara A,Reitz MS Jr

    更新日期：1997-09-01 00:00:00

  • KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements.

    abstract：:Histone acetyltransferases (HATs) catalyze the transfer of an acetyl group from acetyl-CoA to lysine residues of histones and play a central role in transcriptional regulation in diverse biological processes. Dysregulation of HAT activity can lead to human diseases including developmental disorders and cancer. Through...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/s41375-020-1001-z

    authors： Au YZ,Gu M,De Braekeleer E,Gozdecka M,Aspris D,Tarumoto Y,Cooper J,Yu J,Ong SH,Chen X,Tzelepis K,Huntly BJP,Vassiliou G,Yusa K

    更新日期：2020-08-06 00:00:00

  • BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

    abstract：:Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-XL, BCL-2 and MCL-1 contribution to 5-Azacyti...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2014.44

    authors： Bogenberger JM,Kornblau SM,Pierceall WE,Lena R,Chow D,Shi CX,Mantei J,Ahmann G,Gonzales IM,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann RE,Qiu YH,Coombes KR,Cardone M,Braggio E,Yin H,Azorsa DO,Mesa RA,Ste

    更新日期：2014-08-01 00:00:00

  • Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles.

    abstract：:A new factor-independent megakaryoblastic cell line, designated SET-2, was established from the peripheral blood of a patient with leukemic transformation of essential thrombocythemia (ET). SET-2 expressed CD 4, 7, 13, 33, 34, 36, 38, 41, 61, 71, 117, 126, 130 and c-mpl. In addition, it spontaneously produced numerous...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2401608

    authors： Uozumi K,Otsuka M,Ohno N,Moriyama T,Suzuki S,Shimotakahara S,Matsumura I,Hanada S,Arima T

    更新日期：2000-01-01 00:00:00

  • Relationship of factor-induced proliferation to respiratory status in marrow progenitor cells.

    abstract：:We have examined the respiratory status of murine and human marrow progenitor cells proliferating in response to growth factors. Proliferation of fresh marrow cells, which are almost entirely entering terminal differentiation, depends on oxidative phosphorylation as determined by oxygen uptake, lactic acid production,...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：

    authors： Garland JM,Katz F

    更新日期：1987-07-01 00:00:00

  • JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation.

    abstract：:The myeloproliferative neoplasms (MPNs) are characterized by hematopoietic stem/progenitor cell (HSPC) expansion and overproduction of mature blood cells. The JAK2V617F mutation is present in hematopoietic cells in a majority of patients with MPNs, but the mechanism(s) responsible for MPN stem cell expansion remain in...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.114

    authors： Zhan H,Ma Y,Lin CH,Kaushansky K

    更新日期：2016-12-01 00:00:00

  • Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

    abstract：:Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/leu.2016.147

    authors： Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

    更新日期：2016-11-01 00:00:00

  • Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study.

    abstract：:Renal impairment is associated with poor prognosis in multiple myeloma (MM). This subgroup analysis of the phase 3 Assessment of Proteasome Inhibition for Extending Remissions (APEX) study of bortezomib vs high-dose dexamethasone assessed efficacy and safety in patients with relapsed MM with varying degrees of renal i...

    journal_title：Leukemia

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/sj.leu.2405087

    authors： San-Miguel JF,Richardson PG,Sonneveld P,Schuster MW,Irwin D,Stadtmauer EA,Facon T,Harousseau JL,Ben-Yehuda D,Lonial S,Goldschmidt H,Reece D,Bladé J,Boccadoro M,Cavenagh JD,Neuwirth R,Boral AL,Esseltine DL,Anderson KC

    更新日期：2008-04-01 00:00:00

  • Identification of T-cell epitopes for cancer immunotherapy.

    abstract：:The effectiveness of T-cell-mediated immunotherapy of cancer depends on both an optimal immunostimulatory context of the therapy and the proper selection with respect to quality and quantity of the targeted tumor-associated antigens (TAA), and, more precisely, the T-cell epitopes contained in these tumor proteins. Our...

    journal_title：Leukemia

    pub_type： 杂志文章,评审

    doi：10.1038/sj.leu.2404787

    authors： Kessler JH,Melief CJ

    更新日期：2007-09-01 00:00:00

  • Correction: Flow cytometric detection of leukemic blasts in cerebrospinal fluid predicts risk of relapse in childhood acute lymphoblastic leukemia: a Nordic Society of Pediatric Hematology and Oncology study.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Leukemia

    pub_type： 已发布勘误

    doi：10.1038/s41375-020-0821-1

    authors： Thastrup M,Marquart HV,Levinsen M,Grell K,Abrahamsson J,Albertsen BK,Frandsen TL,Harila-Saari A,Lähteenmäki PM,Niinimäki R,Pronk CJ,Ulvmoen A,Vaitkevičienė G,Taskinen M,Schmiegelow K,Nordic Society of Pediatric Hematology a

    更新日期：2020-10-01 00:00:00

  • Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts.

    abstract：:The inv(16)(p13q22) chromosomal rearrangement associated with FAB M4Eo acute myeloid leukemia (AML) subtype is characterized by the presence of the CBFbeta/MYH11 fusion transcript that can be used to detect minimal residual disease (MRD). However, qualitative RT-PCR studies of MRD have so far produced conflicting resu...

    journal_title：Leukemia

    pub_type： 杂志文章

    doi：10.1038/sj.leu.2402478

    authors： Guerrasio A,Pilatrino C,De Micheli D,Cilloni D,Serra A,Gottardi E,Parziale A,Marmont F,Diverio D,Divona M,Lo Coco F,Saglio G

    更新日期：2002-06-01 00:00:00